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The latest publication in the International Agency for
Research on Cancer’s (IARC) series of Handbooks of
Cancer Prevention is focused on breast cancer screening.
The monograph is the outcome of a weeklong meeting of
the Working Group on the Evaluation of Cancer-Preven-
tive Strategies that took place in Lyon, France, March
5–12, 2002. The decision to produce a handbook on
breast cancer screening was timely for several reasons.
First, only a few monographs exist that focus exclusively
on breast cancer screening, none of which represent a
comprehensive treatment of the subject, and all were pub-
lished before 1990 [1–4]. Second, the value of breast
cancer screening recently had been challenged by a
Cochrane Review [5] on screening for breast cancer with
mammography, and a number of independent expert
groups had been assembled to evaluate that analysis and
the authors’ provocative conclusions. Thus, in the pres-
ence of another expert group’s conclusion that there was
no scientific evidence to support the value of mammogra-
phy, the IARC Working Group’s evaluation of the world’s
literature on the efficacy of breast cancer screening had
an extra dimension of drama. Contrary to the Cochrane
Review, the IARC Working Group affirmed the value of
mammography for women aged 50–69.
Anyone interested in breast cancer control, or screening in
general, will find this volume a valuable addition to their
library. The book is well organized, and proceeds through
the evaluation of the scientific evidence in the context of
the classic criteria for principles and practices of screen-
ing for disease established by Wilson and Junger in 1968
[6]. Chapters one through three describe the global
burden and the natural history of breast cancer, concep-
tual considerations related to screening performance,
various methods of early detection, including conventional
and experimental imaging techniques as well as physical
exams, and use of screening and behavioral issues related
to screening uptake. Chapters four through six review con-
ceptual issues and the existing evidence on efficacy,
effectiveness, and cost-effectiveness of screening. The
monograph concludes with a summary chapter, an addi-
tional chapter with a brief description of the conclusions,
and another on recommendations for future research.
Thus, the monograph provides the most extensive treat-
ment available of the issues pertaining to breast cancer
screening. It concludes that mammography is effective in
reducing breast cancer mortality, but like other screening
tests, has a number of limitations.
Undoubtedly, those who are familiar with the literature will
see some topics that are treated with a degree of certainty
that belies the limitations of the existing data, or the pres-
ence of alternative interpretations. If one accepts the
results from the trials uncritically it is reasonable to con-
clude that there is limited evidence to support the efficacy
of screening women aged 40–49. However, the poor per-
formance of screening in the trials in this age group must
be seen as the result of screening intervals that were too
wide to achieve a measurably reduced incidence rate of
advanced disease. Considerable inferential evidence from
the trials [7], meta-analyses [8,9], and evaluations of
service screening [10–12] support the conclusion that,
when women in their forties are screened at a 12–18
month interval, mortality reductions are equivalent to those
that can be expected in women aged 50+ screened every
24 months. Another example of a conclusion that has
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limited supporting evidence is the assertion that 5–25%
of cancers detected by mammography represent over-
diagnosis. While it has been estimated that some over-
diagnosis exists, the overall proportion likely is less than
5%, of which most occurs during a prevalent screen. In
subsequent incident screens the rate is very small to
nonexistent [13,14].
Like many areas of research, experts can and will differ in
the conclusions they draw from existing evidence. Still, the
IARC Handbook on Breast Cancer Screening has much
to offer, and will be required reading for anyone with an
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